Deutsche Bank AG raised its position in shares of La Jolla Pharmaceutical (NASDAQ:LJPC) by 11.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 47,803 shares of the biopharmaceutical company’s stock after acquiring an additional 4,859 shares during the period. Deutsche Bank AG owned approximately 0.18% of La Jolla Pharmaceutical worth $450,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently bought and sold shares of the business. Geode Capital Management LLC raised its stake in La Jolla Pharmaceutical by 3.3% during the 4th quarter. Geode Capital Management LLC now owns 227,484 shares of the biopharmaceutical company’s stock valued at $2,145,000 after acquiring an additional 7,370 shares in the last quarter. Millennium Management LLC acquired a new position in shares of La Jolla Pharmaceutical in the 4th quarter worth $4,623,000. Jane Street Group LLC acquired a new position in shares of La Jolla Pharmaceutical in the 4th quarter worth $134,000. Metropolitan Life Insurance Co. NY grew its holdings in shares of La Jolla Pharmaceutical by 357.4% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 8,699 shares of the biopharmaceutical company’s stock worth $82,000 after acquiring an additional 6,797 shares during the last quarter. Finally, Paloma Partners Management Co acquired a new position in shares of La Jolla Pharmaceutical in the 4th quarter worth $206,000. 93.88% of the stock is owned by hedge funds and other institutional investors.
A number of equities analysts recently issued reports on LJPC shares. Cowen restated a “buy” rating on shares of La Jolla Pharmaceutical in a report on Tuesday, March 5th. ValuEngine upgraded La Jolla Pharmaceutical from a “sell” rating to a “hold” rating in a report on Thursday, April 4th. HC Wainwright reiterated a “buy” rating and set a $26.00 price target on shares of La Jolla Pharmaceutical in a report on Wednesday, April 24th. Finally, Zacks Investment Research upgraded La Jolla Pharmaceutical from a “hold” rating to a “buy” rating and set a $7.75 price target on the stock in a report on Saturday, May 11th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $30.79.
LJPC traded down $0.13 during trading on Friday, reaching $9.71. 1,039,844 shares of the stock traded hands, compared to its average volume of 1,206,797. The stock has a market cap of $263.13 million, a price-to-earnings ratio of -1.24 and a beta of 1.71. La Jolla Pharmaceutical has a fifty-two week low of $5.01 and a fifty-two week high of $38.39.
La Jolla Pharmaceutical (NASDAQ:LJPC) last released its quarterly earnings data on Monday, May 6th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.31) by $0.14. The firm had revenue of $4.40 million during the quarter, compared to analysts’ expectations of $4.98 million. La Jolla Pharmaceutical had a negative return on equity of 337.55% and a negative net margin of 1,324.04%. As a group, research analysts forecast that La Jolla Pharmaceutical will post -4.43 earnings per share for the current year.
About La Jolla Pharmaceutical
La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock.
Featured Story: Bar Chart
Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.